All Over For AZ's Fasenra In COPD With Second Trial Fail
Executive Summary
It is curtains for AstraZeneca's asthma therapy Fasenra as a COPD treatment after the failure of the TERRANOVA trial, which could be good news for GSK's fellow interleukin-5 drug Nucala, despite the latter's own mixed Phase III data.
You may also be interested in...
Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
AZ Explores Orphan Diseases To Boost Fasenra Growth
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.